



Altimune to Announce Second Quarter 2020 Financial Results on August 12

August 5, 2020

GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the three and six months ended June 30, 2020 and its business outlook before the market open and host a conference call on Wednesday, August 12, 2020.

Conference Call Details

Date: Wednesday, August 12
Time: 8:30 am Eastern Time
Domestic: 877-423-9813
International: 201-689-8573
Conference ID: 13706947
Webcast: <http://public.viavid.com/index.php?id=140748>

About Altimune

Altimune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimune, please visit www.altimmune.com.

Investor Contacts:

Will Brown Chief Financial Officer Phone: 240-654-1450 wbrown@altimmune.com	Ashley R. Robinson LifeSci Advisors, LLC 617-430-7577 arr@lifesciadvisors.com
--	---

Media Contacts:

Warren Rizzi
Sard Verbinnen & Co.
Phone: 212-687-8080
altimmune-svc@sardverb.com



Source: Altimune, Inc.